Peptide LibraryResearch statistics
Etelcalcetide research: publications and trials
At a glance
Publications, all years
135
Since 2013
Publications in 2026 so far
8
Through November 1, 2026
Human clinical research
53.4%
71 of 133 classified
Registered clinical trials
20
ClinicalTrials.gov
Randomized controlled trials
23
Publications reporting an RCT in people
Systematic reviews and meta-analyses
4
Preclinical studies
18.0%
16 animal · 5 in vitro · 3 computational
Records that only mention it
27
Not counted above
Status in the library: FDA-approved. 2 publications are not yet classified by study type.
What to keep in mind
- Some completed trials have neither posted results nor a linked results publication.
Publications by year
Etelcalcetide publications by year and evidence
Show the data
| Year | Human clinical research | Preclinical (animal, in vitro, computational) | Reviews and meta-analyses | Other and not yet classified | Total |
|---|---|---|---|---|---|
| 2013 | 2 | 1 | 0 | 0 | 3 |
| 2014 | 1 | 1 | 0 | 0 | 2 |
| 2015 | 3 | 1 | 0 | 0 | 4 |
| 2016 | 0 | 4 | 1 | 0 | 5 |
| 2017 | 9 | 3 | 8 | 4 | 24 |
| 2018 | 5 | 1 | 7 | 2 | 15 |
| 2019 | 7 | 0 | 2 | 1 | 10 |
| 2020 | 6 | 2 | 3 | 1 | 12 |
| 2021 | 10 | 0 | 0 | 0 | 10 |
| 2022 | 8 | 3 | 1 | 0 | 12 |
| 2023 | 6 | 2 | 2 | 3 | 13 |
| 2024 | 5 | 2 | 2 | 1 | 10 |
| 2025 | 5 | 1 | 1 | 0 | 7 |
| 2026 (to date) | 4 | 3 | 0 | 1 | 8 |
Study types
| Observational human study | 27 |
|---|---|
| Randomized controlled trial | 23 |
| Review | 23 |
| Animal study | 16 |
| Other clinical trial | 14 |
| Editorial, letter or other | 8 |
| Case report | 7 |
| In vitro study | 5 |
| Computational study | 3 |
| Meta-analysis | 3 |
| Guideline or consensus | 2 |
| Not yet classified | 2 |
| Correction or retraction notice | 1 |
| Systematic review | 1 |
Research areas
From MeSH major topics. A paper can be in several areas.
| Endocrinology | 109 |
|---|---|
| Metabolic health | 37 |
| Reproductive and sexual health | 33 |
| Musculoskeletal | 19 |
| Cardiovascular | 15 |
| Tissue repair | 3 |
| Immune system | 2 |
| Oncology | 2 |
| Gastrointestinal | 1 |
| Neurological and mental health | 1 |
Registered clinical trials
2 of 17 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.
Completed: 17 · Recruiting: 2 · Terminated: 1
Phase 1: 5 · Phase 2: 6 · Phase 3: 9
Human trials and evidence reviews
Meta-analyses, systematic reviews and trials in people, newest first.
- Calcimimetics treatment strategy for serum calcium and phosphate management in patients with secondary hyperparathyroidism undergoing dialysis: A systematic review and meta-analysis of randomized studies.
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · March 18, 2024 · Meta-analysis · cited 9 times
PMID 38499495 · DOI 10.1111/1744-9987.14125 · Reviews and meta-analyses
- Etelcalcetide versus placebo for secondary hyperparathyroidism in patients receiving hemodialysis: A meta-analysis of randomized controlled trials.
Clinical nephrology · October 1, 2020 · Meta-analysis · cited 2 times
PMID 32729818 · DOI 10.5414/cn110110 · Reviews and meta-analyses
- Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis.
Clinical pharmacokinetics · January 1, 2018 · Meta-analysis · cited 9 times
PMID 28508378 · DOI 10.1007/s40262-017-0550-4 · Reviews and meta-analyses
- Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
American journal of kidney diseases : the official journal of the National Kidney Foundation · May 28, 2020 · Systematic review · cited 80 times
PMID 32475604 · DOI 10.1053/j.ajkd.2020.02.439 · Reviews and meta-analyses
- Effect of etelcalcetide versus alfacalcidol on left ventricular function and feature-tracking cardiac magnetic resonance imaging in hemodialysis-a post-hoc analysis of a randomized, controlled trial.
Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance · November 6, 2023 · Randomized controlled trial · cited 3 times · open access
PMID 37932788 · DOI 10.1186/s12968-023-00975-4 · Human clinical research
- Etelcalcetide Inhibits the Progression of Left Atrial Volume Index Compared to Alfacalcidol in Hemodialysis Patients.
Cardiorenal medicine · September 20, 2023 · Randomized controlled trial · cited 3 times · open access
PMID 37729887 · DOI 10.1159/000533899 · Human clinical research
- Current therapeutic options for the treatment of secondary hyperparathyroidism in end-stage renal disease patients treated with hemodialysis: a 12-month comparative study.
Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego · October 1, 2022 · Randomized controlled trial · cited 5 times
PMID 36283011 · Human clinical research
- Bone Specific Alkaline Phosphatase and Serum Calcification Propensity Are Not Influenced by Etelcalcetide vs. Alfacalcidol Treatment, and Only Bone Specific Alkaline Phosphatase Is Correlated With Fibroblast Growth Factor 23: Sub-Analysis Results of the ETACAR-HD Study.
Frontiers in medicine · July 6, 2022 · Randomized controlled trial · cited 5 times · open access
PMID 35872799 · DOI 10.3389/fmed.2022.948177 · Human clinical research
- Impact of etelcalcetide on fibroblast growth factor-23 and calciprotein particles in patients with secondary hyperparathyroidism undergoing haemodialysis.
Nephrology (Carlton, Vic.) · July 5, 2022 · Randomized controlled trial · cited 8 times · open access
PMID 35749253 · DOI 10.1111/nep.14081 · Human clinical research
- A Phase I, Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Etelcalcetide Administered Intravenously to Chinese Patients With Chronic Kidney Disease Undergoing Hemodialysis.
Clinical therapeutics · November 11, 2021 · Randomized controlled trial · cited 2 times · open access
PMID 34774334 · DOI 10.1016/j.clinthera.2021.09.019 · Human clinical research
Most cited
By OpenAlex citation count. Citations measure attention, not quality or correctness.
- Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
JAMA · January 1, 2017 · Randomized controlled trial · cited 318 times · open access
PMID 28097356 · DOI 10.1001/jama.2016.19468 · Human clinical research
- Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials.
JAMA · January 1, 2017 · Randomized controlled trial · cited 161 times · open access
PMID 28097355 · DOI 10.1001/jama.2016.19456 · Human clinical research
- Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients.
The Journal of pharmacology and experimental therapeutics · May 14, 2013 · Animal study · cited 112 times
PMID 23674604 · DOI 10.1124/jpet.113.204834 · Animal studies
- Critical Cysteine Residues in Both the Calcium-Sensing Receptor and the Allosteric Activator AMG 416 Underlie the Mechanism of Action.
Molecular pharmacology · August 19, 2015 · In vitro study · cited 82 times
PMID 26290606 · DOI 10.1124/mol.115.098392 · In vitro studies
- Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
American journal of kidney diseases : the official journal of the National Kidney Foundation · May 28, 2020 · Systematic review · cited 80 times
PMID 32475604 · DOI 10.1053/j.ajkd.2020.02.439 · Reviews and meta-analyses
Latest publications
- Real-World Etelcalcetide Therapy for Secondary Hyperparathyroidism in Hemodialysis Patients with Inadequate Cinacalcet Response or Intolerance: Prospective Observational Study.
Kidney360 · October 12, 2026 · Observational human study · cited 0 times
PMID 42862647 · DOI 10.34067/kid.0000001416 · Human clinical research
- Regression of uremic tumoral calcinosis following the switch from cinacalcet to etelcalcetide in a hemodialysis patient without severe hyperphosphatemia.
CEN case reports · October 9, 2026 · Case report · cited 0 times · open access
PMID 42853437 · DOI 10.1007/s13730-026-01181-8 · Human clinical research
- Racial and Ethnic Variations in Reductions in Etelcalcetide Use After Withdrawal of the Transitional Drug Add-on Payment Adjustment.
American journal of kidney diseases : the official journal of the National Kidney Foundation · September 8, 2026 · Not yet classified · cited 0 times · open access
PMID 42710611 · DOI 10.1053/j.ajkd.2026.05.024 · Not yet classified
- Etelcalcetide Versus Cinacalcet for Secondary Hyperparathyroidism in Hemodialysis Patients: A Multicentre Comparison with 24 Months of Follow-Up.
Journal of clinical medicine · August 28, 2026 · Observational human study · cited 0 times · open access
PMID 42739661 · DOI 10.3390/jcm15176656 · Human clinical research
- Cost-effectiveness analysis comparison of etelcalcetide, paricalcitol, and cinacalcet for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
Expert review of pharmacoeconomics & outcomes research · August 17, 2026 · Computational study · cited 0 times
PMID 42606099 · DOI 10.1080/14737167.2026.2717287 · Computational studies
- The calcimimetic etelcalcetide restores cardiac function in chronic hyperphosphatemia via calcium sensing receptor-cAMP activation.
Kidney international · April 25, 2026 · Animal study · cited 1 times · open access
PMID 42044867 · DOI 10.1016/j.kint.2026.03.018 · Animal studies
- The calcimimetic etelcalcetide attenuates pressure overload-induced cardiac hypertrophy in rats with and without chronic kidney disease.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · January 30, 2026 · Animal study · cited 0 times · open access
PMID 41619334 · DOI 10.1016/j.biopha.2026.119054 · Animal studies
- [Switching patients from cinacalcet to etelcalcetide: evaluation of predictors of efficacy in a retrospective cohort study].
Problemy endokrinologii · January 18, 2026 · Observational human study · cited 1 times · open access
PMID 41640158 · DOI 10.14341/probl13563 · Human clinical research
- The effects of switching from etelcalcetide to upacicalcet in hemodialysis patients with secondary hyperparathyroidism.
Clinical nephrology · November 1, 2025 · Observational human study · cited 0 times · open access
PMID 40833047 · DOI 10.5414/cn111695 · Human clinical research
- Real-world safety profile of etelcalcetide in dialysis-related secondary hyperparathyroidism: a pharmacovigilance analysis of FAERS data.
Renal failure · July 2, 2025 · Observational human study · cited 2 times · open access
PMID 40605277 · DOI 10.1080/0886022x.2025.2523575 · Human clinical research
How this is counted
PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology
Search terms: AMG 416; Etelcalcetida; Etelcalcetide; Etelcalcetidum; Parsabiv; Telcalcetide; Velcalcetide
((TITLE_ABS:"AMG 416" OR CHEM:"AMG 416" OR TITLE_ABS:"AMG416" OR CHEM:"AMG416") OR (TITLE_ABS:"Etelcalcetida" OR CHEM:"Etelcalcetida") OR (TITLE_ABS:"Etelcalcetide" OR CHEM:"Etelcalcetide") OR (TITLE_ABS:"Etelcalcetidum" OR CHEM:"Etelcalcetidum") OR (TITLE_ABS:"Parsabiv" OR CHEM:"Parsabiv") OR (TITLE_ABS:"Telcalcetide" OR CHEM:"Telcalcetide") OR (TITLE_ABS:"Velcalcetide" OR CHEM:"Velcalcetide")) AND SRC:MED
Cite this page
Peptide Library. (2026, November 2). Etelcalcetide research statistics (Version weekly-2026-11-01) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/etelcalcetide